A PYMNTS Company

EU: Pfizer wins EU approval for $15 billion Hospira buy

By  |  August 4, 2015

US drugmaker Pfizer (PFE.N) gained European Union antitrust approval on Tuesday for its proposed $15 billion acquisition of U.S. rival Hospira (HSP.N) after pledging to sell some drugs to allay competition concerns.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    “The approval is conditional on Pfizer divesting certain sterile injectable drugs, as well as its infliximab biosimilar drug, which is currently under development,” the European Commission said.

    The deal, the biggest ever for Pfizer, will boost its portfolio of generic injectable drugs and copies of biotech medicines.

    Full content: The Wall Street Journal

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.